The research library

The research library.

Every dossier on this page is permanent, search-indexed, and built from public filings. Risks are named where the data shows them. Compensation, where it exists, is disclosed under Section 17(b) on the report itself.

Published dossiers

Roundup editions

Research briefings

100K+

Distribution Reach

Coverage ledger.

Twenty-three companies across Nasdaq, NYSE, NYSE American, OTC, the TSX-V, and the ASX. Each entry links to the full dossier.

> /

Showing 23 of 23

LWAYActive

Lifeway Foods Inc.

NASDAQ, Consumer Staples

$186.8M FY2024 net sales, the fifth consecutive record year. Roughly 20 straight quarters of year-over-year growth. Danone holds about 23% and has bid twice.

$422.6M FY2024 net sales in single-use foodservice packaging. Consistently profitable, with a regular quarterly dividend and a history of specials.

Read the dossier

IIINActive

Insteel Industries Inc.

NYSE, Industrials

The largest U.S. maker of steel wire reinforcing for concrete construction, working through a cyclical trough: $529.0M FY2024 net sales against an $826.8M FY2022 peak.

40 consecutive quarters of record revenue. ARR at $40M. 131,000+ customers. DOJ enforcement tailwind.

$68.2M FY2025 revenue, 12% growth, GAAP net income of $5.1M. $31.4M in cash, up 72.5%.

$164.48M FY2025 revenue, 15.2% growth. U.S. revenue up 101.6% in H1 FY2026.

Revenue grew 140% to $108M in FY2024. Q3 2025 revenue $30.5M, up 33% year over year. HPC and AI cloud services.

$84M in cash after a 2025 equity raise. FY2025 revenue $7.73M, up 17.8%. 25 years in commercial drones.

$36.35M in stable revenue. GDM segment growing 18.1% in H1 2025. $25M cash position.

$22.4M cash. Binding MOU with Indian Railways via Sujan Ventures. Follow-on mining order from Latin America.

Revenue growing, gross margins expanded from 7% to 15% in two quarters, cash operating burn down 95%.

$150M BARDA contract. DeepView FDA De Novo application submitted, determination pending. Revenue of $19.7M.

$13.3M cash, zero debt, runway into 2028. NOCISCAN scan volume up 89% year over year.

94% gross margins on restated net revenue. Seven consecutive profitable quarters. Clean FDA inspection.

Read the dossier

GLMDActive

Galmed Pharmaceuticals

NASDAQ, Biotech

$19.2M in cash against a market cap in the same range. Aramchol Phase 3 open-label showed 65% fibrosis improvement.

Revenue grew from $0.6M to $6.7M in six quarters. 333% year-over-year growth in Q1 FY2026. American-assembled.

Read the dossier

ENTEFActive

ESE Entertainment Inc.

OTC / TSX-V, Entertainment

Bombee posted CAD $3.745M in a single quarter, 109% sequential growth. First positive EBITDA.

Read the dossier

WEBMonitoring

Web Travel Group Ltd.

ASX, Travel Technology

B2B online travel marketplace. WebBeds sources hotel inventory globally for travel-trade buyers.

Revenue up 20% to $2.2M in FY2025. Gross margin expanded 840 basis points to 62.5%. E-commerce up 88%.

Read the dossier

PAPLMonitoring

Pineapple Financial Inc.

NYSE American, Financial Services

Agent network grew 82% year over year. FY2025 gross billings $17.4M. Operating losses improved 22.9%.

Read the dossier

PRPBMonitoring

CC Neuberger Principal Holdings II

NYSE, SPAC

Special purpose acquisition company. A blank-check vehicle formed to identify and merge with a private business.

$32.2M in cash as of September 2025, up from $4.1M in December 2024. Engineering services generating near-term revenue.

Read the dossier

AREBMonitoring

American Rebel Holdings Inc.

NASDAQ, Consumer

Going concern disclosed Q3 2025. Nine-month revenue down 25% year over year. $22.5M in debt. Risks named in full.

Read the dossier

No coverage matches that search. Clear it to see all 20 dossiers.

Research and compliance briefings.

How disclosed research works, what it costs, and why the coverage gap exists. Written for IR teams, CFOs, and investors doing diligence on the model itself.

Start hereResearch & Compliance

Is issuer-paid (sponsored) stock research legal?

Yes, when the compensation is disclosed. Section 17(b), the SEC enforcement record, and what compliant disclosure looks like.

For public companies

How to get research coverage for a micro-cap company.

A practical guide for CFOs and IR directors at companies between $10M and $200M in market cap: the three kinds of research coverage, what a company needs before it asks, how to evaluate a research vendor, and what a compliant deliverable looks like..

Research & Compliance

Vendor due diligence for sponsored research: ten questions before you sign.

A due diligence checklist for CFOs, general counsel, and IR directors evaluating an issuer-paid research provider: disclosure, sourcing, ownership policy, distribution, permanence, and the contract terms that separate research from promotion..

Market Structure

The Nasdaq minimum bid price rule: the one deadline that is actually dated.

How the Nasdaq $1 minimum bid price requirement works: the 30 consecutive business days that start the clock, the deficiency notice a company must disclose, the 180-day cure period, the possible second period, and why a delisting can cost a company its fastest route to capital..

Market Structure

How investors actually find micro-cap stocks, and what they find when they search yours.

Where micro-cap investors discover companies in practice: screeners, SEC EDGAR, ticker search, communities, and newsletters.

Research & Compliance

The weekly roundup.

The market did something. Here is what it meant. Eighteen editions and counting, each with a micro-cap read on the week.

Latest edition & full archive

Start with the current week, then work backward through the ledger.

Open the roundup

#018 #017 #016 #015 #014 #013 #012 #011 #010 #009 #008 #007 #006 #005 #004 #003 #002 #001

For public companies.

Coverage begins with an eligibility review against documented criteria. Companies that do not meet the standard are declined. Compensation is disclosed under Section 17(b) on every report.

Institutional Partnership Coverage and distribution

For investors.

New dossiers and roundup editions, delivered when they publish. The research is free to read. The podcast covers the week in micro-caps.

Subscribe Listen to the podcast

DisclosureWLW Holdings LLC may receive compensation from issuers whose securities are featured in research distributed through this platform. All compensation is disclosed per Section 17(b) of the Securities Act of 1933 on each respective report page. Nothing on this website constitutes investment advice. All investing involves risk.